Cereno Scientific strengthens its Executive Management Team with recruitment of Chief Business Officer
Cereno Scientific (XSAT: CRNO B) today announced Etienne Adriansen to the newly created position of Chief Business Officer, as of March 1, 2023. The appointment adds commercial expertise and capacity to Cereno's Executive Management Team as business development is an active and important component of the company’s growth strategy.
"I am very pleased to welcome Etienne Adriansen to Cereno. He will be a strong addition to our Executive Management Team, heading up our business development and commercialization efforts. Etienne brings extensive experience from strategic portfolio management, commercialization, licensing and business transactions, and he will play a significant role in establishing strategic partnerships for Cereno. Etienne will ensure commercial viability of our highly promising drug portfolio with CS1 in Phase II, and two preclinical programs, CS014 and CS585, both in preparation for clinical development,” says Sten R. Sörensen, CEO at Cereno Scientific.
As Chief Business Officer, Etienne will be responsible for establishing and leading Cereno’s business development, leveraging his expertise in business strategy, portfolio management, licensing, transactions and establishing strategic collaborations. Etienne has an M.Sc. in Business Administration & Commercial Law and holds over 20 years of collected experience in various commercial roles, business development and R&D from companies such as Lundbeck, Nycomed and LEO Pharma. Etienne joins Cereno from Cessatech where he held the role of Senior Director Business Development.
For further information, please contact:
Josefine Göranson, Head of IR & Communications
Phone: +46 704 92 35 63
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.